Introduction：Basic information about CAS 442908-10-3|Vipadenant, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Vipadenant |
|---|
| CAS Number | 442908-10-3 | Molecular Weight | 321.33700 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C16H15N7O | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine |
|---|
| Synonym | More Synonyms |
|---|
Vipadenant BiologicalActivity
| Description | Vipadenant is an adenosine receptor antagonist, with Kis of 1.3 nM and 68 nM for A2A and A1, respectively. |
|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Adenosine ReceptorResearch Areas >>Neurological Disease |
|---|
| Target | Ki: 1.3 nM (A2A), 68 nM (A1)[1], 1005 nM (A3)[2] |
|---|
| In Vivo | Vipadenant (0.3-30 mg/kg) produces a dose-dependent reduction in catalepsy. Vipadenant (10 mg/kg) does not produce any statistically significant dyskinetic episodes in 6-OHDA-lesioned rats during a 19-day dosing regimen[1]. In the mouse and rat haloperidol-induced hypolocomotion models, vipadenant has a minimum effective dose of 0.1 and 1 mg/kg, respectively. Vipadenant (3 and 10 mg/kg, p.o.) is able to increase contralateral rotations in 6-OHDA lesioned rats[2]. |
|---|
| References | [1]. Jones N, et al. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. Brain Res Bull. 2013 Sep;98:163-9. [2]. Brian C. Shook, et al. Adenosine A2A Receptor Antagonists and Parkinson’s Disease. ACS Chem Neurosci. 2011 Oct 19; 2(10): 555-567. |
|---|
Chemical & Physical Properties
| Molecular Formula | C16H15N7O |
|---|
| Molecular Weight | 321.33700 |
|---|
| Exact Mass | 321.13400 |
|---|
| PSA | 122.40000 |
|---|
| LogP | 2.51370 |
|---|
| Storage condition | 2-8℃ |
|---|
Synonyms
| VER-ADO-49 |
| VER-A00-11 |
| Vipadenant |
| V-2006 |
| CEB-4520 |
| UNII-LDR3USH1NJ |
